Beta Bionics (Nasdaq:BBNX) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of BBNX rose around 20% to $29 apiece in post-market trading today. The Irvine, California-based automated insulin delivery device maker reported losses of $14 million. That equals 33¢ per share on sales of […]
Drug-Device Combinations
Orchestra BioMed, Terumo terminate drug-eluting balloon distro deal in $30M agreement
Orchestra BioMed (Nasdaq:OBIO) announced today that it entered into a termination and right of first refusal agreement with Terumo. The agreement relates to the New Hope, Pennsylvania-based company’s Virtue Sirolimus AngioInfusion Balloon (SAB). It supersedes and terminates a prior distribution agreement between the companies and grants Terumo a right of first refusal (ROFR) to acquire […]
ViCentra adds Dexcom, Medtronic Diabetes veterans to leadership team
ViCentra announced today that it appointed former Dexcom and Medtronic Diabetes leaders to new executive roles. The Dutch insulin pump maker continues to expand its senior leadership as it looks to advance its Kaleido patch pump system. It appointed Karen Baxter, former VP and GM at Dexcom, to the position of SVP of sales for […]
Dexcom adds Stanford Medicine chair to its board of directors
Dexcom (Nasdaq:DXCM) announced today that it appointed Dr. Euan Ashley to its board of directors, effective Oct. 24, 2025. Ashley, a renowned researcher, entrepreneur and clinician, brings extensive leadership experience across healthcare research institutions and private organizations. He currently serves as chair of the Dept. of Medicine at Stanford Health. Research areas for Ashley span […]
Boston Scientific shares positive Agent drug-coated balloon findings
Boston Scientific (NYSE: BSX) today shared findings from new analyses of its Agent drug-coated balloon (DCB). Agent serves as an alternative to traditional therapies like balloon angioplasty, additional layers of stenting or radiation. The paclitaxel-coated balloon transfers a therapeutic dose of drug to the vessel wall, helping to prevent in-stent restenosis (ISR) reoccurrence. The FDA […]
Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial
Orchestra BioMed (Nasdaq:OBIO) today announced the first patient enrollments in a study of its Virtue Sirolimus AngioInfusion Balloon (SAB). The FDA investigational device exemption (IDE) trial compares the Virtue SAB to the Boston Scientific Agent paclitaxel-coated balloon. Agent is currently the only FDA-approved drug-coated balloon (DCB) for coronary indication, picking up approval in March. New Hope, […]
Vivani prices $15.7M offering
Vivani Medical (Nasdaq:VANI) announced that it priced a best efforts registered direct offering of 6 million shares of common stock. The Alameda, California-based company priced the shares at $1.62 apiece. It also announced a concurrent private placement of more than 3.7 million shares of common stock at the same price. Gregg Williams, the company’s board […]
Multiple studies back Cordis Selution SLR drug-eluting balloon
Cordis today announced new findings from a duo of studies supporting the use of its Selution SLR drug-eluting balloon (DEB) system. Miami Lakes, Florida-based Cordis announced results from the SELUTION DeNovo and SELUTION 4ISR trials at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. Both randomized clinical trials demonstrated positive outcomes that met […]
Ypsomed launches YpsoLoop autoinjector platform designed for circularity
Ypsomed announced that it launched YpsoLoop, its first autoinjector platform designed for circularity. The Swiss drug delivery device maker says the two new 1 mL and 2.25 mL platforms enable material recovery. Their design enables automated disassembly and efficient recycling while offering the convenience of a pre-filled, two-step autoinjector. Ypsomed said the YpsoLoop platform integrates […]
Insulet adds JPMorgan veteran to its board of directors
Insulet (Nasdaq:PODD) announced today that it appointed Robert “Robbie” L. Huffines to its board of directors. Huffines, a former global chair of investment banking at JPMorgan Chase & Co., joins the automated insulin delivery technology maker’s board effective Oct. 31, 2025. He joins as an independent director and a member of the Insulet Audit Committee. […]









